UNITED-GUARDIAN REPORTS SECOND QUARTER RESULTS Hauppauge, NY, August 7, 2026 – United-Guardian, Inc. (NASDAQ:UG) announced today the financial results for the second quarter and first half of 2026. Second quarter net sales increased by 10% from…
UNITED-GUARDIAN REPORTS
SECOND QUARTER RESULTS
Hauppauge, NY, August 7, 2026 – United-Guardian, Inc. (NASDAQ:UG) announced today the financial
results for the second quarter and first half of 2026. Second quarter net sales increased by 10% from
$2,838,225 in 2025 to $3,108,267 in 2026, with net income increasing 16% from $626,826 ($0.14 per share)
to $728,579 ($0.16 per share). Net sales for the six-month period ended June 30
th
increased by 12% from
$5,319,352 in 2025 to $5,980,489 in 2026, and net income increased by 30% from $1,187,721 ($0.26 per
share) to $1,547,481 ($0.34 per share).
Donna Vigilante, President of United-Guardian, stated, “I am pleased to report that sales and earnings
increased in both the second quarter and first half of 2026. Sales of our cosmetic ingredients and
pharmaceutical products increased during both periods compared with the same periods in 2025. Cosmetic
ingredient sales increased by 44% in the second quarter and 34% in the first half of 2026 compared with
the same periods in 2025. The growth in cosmetic ingredient sales was primarily attributable to increased
purchases by Ashland Specialty Ingredients (“ASI”), our largest cosmetic distributor. ASI had experienced
higher-than-normal inventory levels in 2025, which have since been reduced, resulting in the resumption
of regular purchasing levels in the first half of 2026. Pharmaceutical sales increased by 1% in the second
quarter and 11% in the first half of 2026 compared with the same periods in 2025, with Renacidin
®
, our
most important pharmaceutical product, serving as the primary driver of growth.”
“As we move through 2026, we remain focused on our growth plan, which includes expanding promotional
efforts and increasing market awareness for Renacidin, particularly among physicians and care providers;
increasing awareness of our “natural” products; and growing our medical lubricant business.”